OrganiGram Holdings, Inc. (OGRMF)

organigram_logoOrganiGram Holdings, Inc is a Canadian company that develops, produces, and sells condition-specific medicinal marijuana. A licensed producer under Canada’s Marihuana for Medical Purposes Regulations (MMPR), the company currently has 16 strains of medical cannabis in production, and it is developing more.

Condition-specific marijuana means that it targets particular health conditions with a specific formulation using THC and/or CBD, which are the plant’s principal medicinal ingredients. Such treatment can be used for the symptoms or side-effects in patients with HIV/AIDS, cancer, anxiety, muscular dystrophy, spinal cord disease, arthritis, and many others.

OrganiGram’s marijuana strains are grouped into the following: stimulating appetite and controlling nausea (ACN); anxiety and stress disorders (ASD) including PTSD; managing chronic pain (MCP) using marijuana’s analgesic effects; neurological disorders and spasticity (NDS); and dignity, comfort, and quality of life (DCQ) for terminal illnesses and end-of-life care.

OrganiGram markets its products to both patients and doctors interested in medical cannabis. The company sells the products through telephone orders and online stores. In September 2014, it made its first shipment of medical marijuana products to registered and shortlisted customers.

The company was founded as Inform Exploration Corp in 2010. At that time, it was based in Vancouver and engaged in the acquisition and exploration of resource properties. It then became OrganiGram Holdings, Inc only in August 2014, following a reverse takeover.

Today, OrganiGram Holdings, Inc is based in New Brunswick. It is listed in the TSX Venture Exchange under the ticker symbol OGI, and in the US OTC markets under the symbol OGRMF. It has a market value pegged at USD 64.9 M. The company’s top-level executives include Denis Arsenault, Chairman, CEO, and President; Scott Franklin, CFO; and Brett Allan, Director of Investor Relations.

Yahoo! Finance: OGRMF News

Latest Financial News for OGRMF

CGC, HEXO, CTST Moving Higher Today

CGC, HEXO, CTST Moving Higher TodayCannabis sector gains Today, the Horizons Marijuana Life Sciences ETF (HMMJ) gained about 0.3% and the ETFMG Alternative Harvest ETF (MJ) gained about 0.3% in the first half of the trading session. However, the

Cannabis stocks rally after 3 surveys find Americans increasingly favor legalization

Cannabis stocks rose across the board on Tuesday, as three separate surveys found Americans are increasingly in favor of legalization, demonstrating a major shift in opinion over the last two decades.

Aphria Trading Higher After the Big Selloff Yesterday

TLRY, CGC, ACB Snap Out of Their Losing Streaks(Continued from Prior Part)Aphria trading higher Aphria (APHA) lost about 14% in yesterday’s trading session after it reported its earnings. The company wrote off 50 million Canadian dollars relating

Cannabis Stock on Focus: Laying Out the Game-Plan for Marijuana Producer OrganiGram

The main thesis in the cannabis sector for 2019 has been looking beyond the few major Canadian players that grabbed all of the financial headlines last year. OrganiGram Holdings (OGRMF) (TSE:OGI) is another company that follows the script of being under the radar and not listed on the major stock exchanges. The company doesn’t have the preferred access to the substantial U.S. market, but OrganiGram still offers a great growth opportunity in Canada without the wild spending for risky international expansion.Not So SmallOrganiGram posted FQ2 results through the end of February providing a view into 2019 adult-use recreational sales. The quarterly net revenues of C$26.9 million more than doubled from the previous quarter and places the company on the scale of some of the much better known Canadian companies. A prime example is the Cronos Group (CRON) that only reported C$15.7 million in revenues for all of 2018, yet the stock has a listed market value of over $5 billion.Even more important, OrganiGram hasn’t taken on aggressive expansion plans whether domestically or internationally so margins have remained relatively strong. For the quarter, gross margins were a strong 60% and adjusted EBITDA stayed a very healthy 49% of sales. Other major Canadian players only hope reach positive EBITDA numbers this year.After converting some debt, the company has a fully diluted share count of 165 million shares. The stock valuation is only roughly $1.1 billion despite doubling off the market lows in December. Most Canadian cannabis stocks trade at roughly 10x future sales that extend into 2020 or 2021 while this stock is closer to 10x the current sales rate that now exceeds C$100 million.Plenty Of GrowthLike most of the cannabis players in North America, OrganiGram has a plan to grow cultivation and enter the edibles and beverages segment when Canada opens it up last this year. The key here is building for reasonable growth, instead of wild expansion plans.OrganiGram is the process of tripling current production capacity to a reasonable 113,000 kg/year from 36,000 kg/year once completed later this year. In addition, the company has a 56,000 square feet building for Phase 5 expansion to cover the derivatives launch this year.The company expects to have several products available for sale including vape pens, chocolate edibles and a beverage product with an extended shelf live. By having products ready in quantities as needed and not on the bleeding edge, OrganiGram hasn’t needed wild share dilution. The cannabis company even has a cash balance of C$63 million at the end of February.Going forward, OrganiGram is positioned to need additional capital to expand as opposed for running operations at the wild losses of the major players such as the above-mentioned Cronos Group.TakeawayThe key investor takeaway is that companies like OrganiGram aren’t garnering the investor headlines since they aren’t undertaking excessive growth plans or listed on major stock exchanges. The lack of major headlines makes a stock like this a better value for investors.Wall Street’s confidence backing this cannabis stock is strong, with TipRanks analytics showcasing OrganiGram stock as a Strong Buy. Based on 11 analysts polled in the last 3 months, all 11 rate a Buy on the stock.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Disclosure: The author has no position in OrganiGram stock.More on OrganiGram: OrganiGram Remains a Buy, Says Jefferies More recent articles from Smarter Analyst: * With Streaming More Popular, Is Roku (ROKU) Stock a Good Investment? * Aurora Cannabis (ACB) Stock Is in Position for Another Bullish Leg * After Netflix (NFLX) Earnings, Is It Time to Buy the Stock? * And the Winner of the Week Is... Qualcomm (QCOM) Stock

How Cannabis Companies’ Upside Potential Stacks Up

Why Did Cannabis Stocks Fall on April 15?(Continued from Prior Part)Cannabis stocks Cannabis stocks were deep in the red on April 15. The sector is known for high volatility. Stocks in the cannabis space are more volatile compared to broader